Descriptive Analysis of Patient Readmissions Within 60 Days Due to Medication-Related Events.

Background: Hospital readmissions have become a marker for quality health care. Readmissions secondary to failures of the medication use process are poorly documented and underrecognized.

Objective: To identify the incidence of readmissions related to the medication use process and identify associated patient- and therapy-related risk factors.

A new epoprostenol formulation for the treatment of pulmonary arterial hypertension.

Purpose: The pharmacology and pharmacokinetics of a novel formulation of epoprostenol for the treatment of pulmonary arterial hypertension (PAH) are reviewed, with guidance on addressing a number of important safety considerations.

Summary: Epoprostenol is a direct vasodilator of the pulmonary and systemic vasculature indicated for improving exercise capacity in patients with PAH. Veletri, a recently approved formulation of epoprostenol for continuous i.